Section of Inflammation and Cardiometabolic Diseases, National Heart Lung and Blood Institute, Bethesda, MD, USA.
J Transl Med. 2013 Aug 22;11:194. doi: 10.1186/1479-5876-11-194.
Moderate-to-severe psoriasis is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); however, the link is poorly understood.
Skin and serum from patients with psoriasis were evaluated to understand if there was evidence of dysregulation in a targeted group of inflammatory and lipid genes related to ASCVD. Microarray analyses of expression of targeted ASCVD genes from skin in 89 patients with moderate-to-severe psoriasis from the ACCEPT trial were compared with non-diseased skin from healthy controls (n = 25). Serum (n = 149) was tested at baseline for monocyte chemoattractant protein-1 (MCP-1), macrophage-derived chemokine (MDC), and apolipoprotein-A1 (Apo-A1) comparing to healthy controls (n=162).
An increase in skin gene expression for MCP-1 (7.98-fold) and MDC (6.66-fold) (p < 0.001 each) was observed in lesional versus healthy skin. Significant decreases in liver X receptor-alpha (LXR-α) (-5.94-fold), a protective lipoprotein metabolism gene, and in peroxisome proliferator-activated receptor-alpha (PPAR-α) (-7.58-fold), a protective anti-inflammatory and lipid modulating gene, were observed in lesional versus healthy skin (p < 0.001 each). Serum analyses revealed that MCP-1 (502 vs. 141 pg/mL) and MDC (1240 vs. 409 pg/mL) levels were significantly elevated in psoriasis compared with healthy controls (p < 0.001 each). Dysregulated lipid metabolism was also evident in the serum, as Apo-A1, a protein product related to PPAR-α activation, was significantly decreased in patients with psoriasis compared with healthy controls (25.2 vs. 38.9 mg/dL; p < 0.001).
Analyses of targeted genes and their products known to be associated with ASCVD revealed dysregulation of inflammatory (MCP-1 and MDC) and lipid metabolism (LXR-α, PPAR-α) genes in psoriasis. These findings provide evidence of a potential shared pathophysiology linking psoriasis to cardiometabolic diseases.
中重度银屑病与动脉粥样硬化性心血管疾病(ASCVD)的风险增加有关;然而,其关联机制尚不清楚。
评估银屑病患者的皮肤和血清,以了解靶向 ASCVD 相关炎症和脂质基因的特定基因是否存在失调。对来自 ACCEPT 试验的 89 例中重度银屑病患者皮肤的靶向 ASCVD 基因进行微阵列分析,并与健康对照者(n=25)的非病变皮肤进行比较。在基线时,对来自 149 例患者的血清进行单核细胞趋化蛋白-1(MCP-1)、巨噬细胞来源趋化因子(MDC)和载脂蛋白-A1(Apo-A1)的检测,并与健康对照者(n=162)进行比较。
与健康皮肤相比,皮损皮肤中 MCP-1(7.98 倍)和 MDC(6.66 倍)(p<0.001)的基因表达增加。在皮损皮肤中,保护性脂蛋白代谢基因肝 X 受体-α(LXR-α)(-5.94 倍)和保护性抗炎和脂质调节基因过氧化物酶体增殖物激活受体-α(PPAR-α)(-7.58 倍)的表达显著下降(p<0.001)。血清分析显示,与健康对照组相比,银屑病患者的 MCP-1(502 vs. 141 pg/mL)和 MDC(1240 vs. 409 pg/mL)水平显著升高(p<0.001)。在血清中也观察到脂质代谢失调,因为 Apo-A1 是与 PPAR-α 激活相关的蛋白产物,与健康对照组相比,银屑病患者的 Apo-A1 明显降低(25.2 vs. 38.9 mg/dL;p<0.001)。
对已知与 ASCVD 相关的靶向基因及其产物的分析显示,银屑病中炎症(MCP-1 和 MDC)和脂质代谢(LXR-α、PPAR-α)基因失调。这些发现为银屑病与心血管代谢疾病之间存在潜在共同发病机制提供了证据。